![](https://investorshub.advfn.com/uicon/6218.png?cb=1615491815)
Monday, January 22, 2018 11:16:16 AM
Isn't this what CTD Holdings is attempting to do?
What was/is the relationship between CTDH and the Hemples? If CTDH suddenly went to $20.00 per share, would the Hemples go after CTDH for money?
Help me connect the dots...
This from 2009
June 12, 2009 08:00 ET
CTD Holdings Moves Ahead on Research Park Project
HIGH SPRINGS, FL--(Marketwire - June 12, 2009) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced that ViStra Growth Partners, Inc. (VGP), the newly created subsidiary of CTD, has agreed to present a preliminary project plan to the CTD board of directors by year end, 2009, for the proposed "Joszef Szejtli Cyclodextrin Research Park." Mr. Louis Weltman, the President/CEO of VGP, has considerable experience with commercial property development for such purposes. Rick Strattan, the Chairman/CEO of CTDH, stated that, "This project has been on the back burner at CTDH ever since we paid off the mortgage on the 40 acre corporate site in 2007. The convergence of CTDH's work with Chris Hempel to get Trappsol® HPB into a compassionate use study for her twin girls with Niemann-Pick disease, a form of childhood Alzheimer's, and working with the expertise of Lou Weltman and his knowledge of 501(c)3 organizations has really crystallized for me what the mission of the Research Park will be."
Mr. Strattan continues, "Chris Hempel has done more in the last 18 months to introduce the worldwide public and regulatory agencies to the amazing properties of Cyclodextrins, than the entire industry has been able to do in the last 20 years."
Ms. Hempel's exploits, efforts and successes are available on the web at www.addiandcassi.com and www.webofhope.com.
--------------
THEN WE HAVE THIS FROM THE HEMPLES WEBSITE:
According to the suit, Cydan first approached the Hempels about a partnership to develop cyclodextrin in 2013.
Soon after reaching out to the Hempels and agreeing to a joint venture, Cydan formed Vtesse, a company dedicated to developing drugs for Niemann-Pick Disease Type C and other rare diseases. In April 2017, Vtesse was purchased by Sucampo Pharmaceuticals for $200 million, in large part because of the same treatment, the suit says, the Hempels were in contract to develop.
-------------
Is it not true that most investors in CTDH believe that the Hemples were cooperating with CTDH?
In the statement above we then learn that the Hemples were in discussions with Cydan in 2013 to develop a partnership.
So if the Hemples and Cydan (latter VTESSE, etc) were to form a partnership --- WHERE WOULD THAT LEAVE CTDH?
If CTDH is the clear winner in this as you suggest, WHY WERE THE HEMPLES GOING TO DO A DEAL WITH CYDAN?
Lots of questions; lots of intrigue. Should be interesting to watch.
Recent CYTH News
- Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 • Business Wire • 06/25/2024 01:25:00 PM
- Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 06/14/2024 08:01:00 PM
- Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 • Business Wire • 05/30/2024 01:00:00 PM
- Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/16/2024 12:05:00 PM
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:46:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:45:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:44:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:43:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:42:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:41:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:40:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:44:54 PM
- Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office • Business Wire • 01/29/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:01:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:50:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:48:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:28:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:25:09 AM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:21 PM
- Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 • Business Wire • 12/18/2023 02:15:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM